退行性二尖瓣修复远处转诊的经济学分析与长期随访
本研究比较了26例远距离转诊与104例本地患者在退行性二尖瓣修复中的经济价值和长期结局。结果显示两组费用与支付无显著差异,5年生存率分别为97%和100%,远距离转诊至二尖瓣参考中心具有成本效益。
要点
- 远距离转诊至二尖瓣参考中心不增加额外费用,且长期生存结局相似。
- 远距离转诊可为支付方和患者带来净社会效益。
- 对于低风险退行性二尖瓣修复患者,远距离转诊是合理可行的。
核心结论
- 远距离转诊至二尖瓣参考中心是可行且合理的,具有经济学价值。
主要发现
- 两组年龄、射血分数、手术时间、输血和瓣环尺寸无差异。
- 成本效益分析显示远距离转诊至二尖瓣参考中心可为支付方带来436至6078美元净收益,为患者带来22163至30067美元净收益,社会总收益估计为22599至32528美元。
临床怎么用
- 对于低风险退行性二尖瓣修复患者,可考虑远距离转诊至二尖瓣参考中心以提高修复几率,且不增加经济负担。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the superiority of mitral valve repair (MVr) over replacement for degenerative disease, repair rates vary widely across centers. Traveling to a mitral reference center (MRC) is 1 way to increase the odds of MVr. This study assessed the economic value (quality/cost) and long-term outcomes of distant referral to an MRC. METHODS: Among 746 mitral surgery patients between January 2011 and June 2013, low-risk patients with an ejection fraction greater than 40% undergoing isolated degenerative MVr were identified and included 26 out-of-state (DISTANT) and 104 in-state patients (LOCAL). Short- and long-term outcomes and institutional financial data (including travel expenses) were used to compare groups. National average and MRC-specific MVr rates, clinical outcomes, and marginal value of quality-adjusted life-years collected from The Society of Thoracic Surgeons database and Medicare estimates were used to perform a nationally representative cost-benefit analysis for distant referral. RESULTS: Age, ejection fraction, operative time, blood transfusions, and annuloplasty ring size did not differ between groups. Median charges were $76,022 for LOCAL and $74,171 for DISTANT (P = .35), whereas median payments (including travel expenses) were $57,795 for LOCAL and $58,477 for DISTANT (P = .70). Short- and long-term outcomes were similar between groups and median follow-up was 7.1 years. Estimated 5-year survival was 97% (96% for LOCAL and 100% for DISTANT; P = .24). Cost-benefit analysis showed a net benefit through distant referral to an MRC ranging from $436 to $6078 to the payer and $22,163 to $30,067 to the patient, combining for an estimated $22,599 to $32,528 societal benefit. CONCLUSIONS: These data suggest that distant referral to an MRC is achievable and reasonable.
引用
- Brescia AA, Paulsen MJ, Watt TMF, et al. Economic Analysis and Long-term Follow-up of Distant Referral for Degenerative Mitral Valve Repair. Ann Thorac Surg. 2020. PMID: 32693045. doi:10.1016/j.athoracsur.2020.05.114
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。